Literature DB >> 31653641

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.

Carmine De Angelis1,2,3, Chandandeep Nagi1, Cliff C Hoyt4, Linying Liu4, Kristin Roman4, Chichung Wang4, Yi Zheng4, Jamunarani Veeraraghavan1,2, Vidyalakshmi Sethunath1,2, Paolo Nuciforo5, Tao Wang1, Anna Tsimelzon1,2, Sufeng Mao1,2, Susan G Hilsenbeck1,2, Meghana V Trivedi1,2,6, Maria Letizia Cataldo1,2,3, Anne Pavlick1, Antonio C Wolff7, Britta Weigelt8, Jorge S Reis-Filho8, Aleix Prat9,10, Carolina Gutierrez1,2, Charles Kent Osborne1,2, Mothaffar F Rimawi1,2, Rachel Schiff11,2.   

Abstract

PURPOSE: Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2+ breast cancer. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab treatment is unclear.Experimental Design: Hematoxylin and eosin-stained slides (n = 59) were used to score stromal (s-)TILs from pretreatment biopsies of patients enrolled in the neoadjuvant TBCRC006 trial of 12-week lapatinib plus trastuzumab therapy (plus endocrine therapy for ER+ tumors). A 60% threshold was used to define lymphocyte-predominant breast cancer (LPBC). Multiplexed immunofluorescence (m-IF) staining (CD4, CD8, CD20, CD68, and FoxP3) and multispectral imaging were performed to characterize immune infiltrates in single formalin-fixed paraffin-embedded slides (n = 33).
RESULTS: The pathologic complete response (pCR) rate was numerically higher in patients with LPBC compared with patients with non-LPBC (50% vs. 19%, P = 0.057). Unsupervised hierarchical clustering of the five immune markers identified two patient clusters with different responses to lapatinib plus trastuzumab treatment (pCR = 7% vs. 50%, for cluster 1 vs. 2 respectively; P = 0.01). In multivariable analysis, cluster 2, characterized by high CD4+, CD8+, CD20+ s-TILs, and high CD20+ intratumoral TILs, was independently associated with a higher pCR rate (P = 0.03). Analysis of single immune subpopulations revealed a significant association of pCR with higher baseline infiltration by s-CD4, intratumoral (i-) CD4, and i-CD20+ TILs.
CONCLUSIONS: LPBC was marginally associated with higher pCR rate than non-LPBC in patients with lapatinib plus trastuzumab treated HER2+ breast cancer. Quantitative assessment of the immune infiltrate by m-IF is feasible and may help correlate individual immune cell subpopulations and immune cell profiles with treatment response. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31653641      PMCID： PMC7002194          DOI： 10.1158/1078-0432.CCR-19-1402

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  39 in total

1.  Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.

Authors:  Jason R Brown; Hallie Wimberly; Donald R Lannin; Christian Nixon; David L Rimm; Veerle Bossuyt
Journal:  Clin Cancer Res       Date:  2014-09-25       Impact factor: 12.531

2.  Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.

Authors:  M V Dieci; A Prat; E Tagliafico; L Paré; G Ficarra; G Bisagni; F Piacentini; D G Generali; P Conte; V Guarneri
Journal:  Ann Oncol       Date:  2016-08-02       Impact factor: 32.976

3.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

4.  Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.

Authors:  Yul Ri Chung; Hyun Jeong Kim; Min Hye Jang; So Yeon Park
Journal:  Breast Cancer Res Treat       Date:  2016-12-02       Impact factor: 4.872

5.  Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Authors:  Edith A Perez; E Aubrey Thompson; Karla V Ballman; S Keith Anderson; Yan W Asmann; Krishna R Kalari; Jeanette E Eckel-Passow; Amylou C Dueck; Kathleen S Tenner; Jin Jen; Jian-Bing Fan; Xochiquetzal J Geiger; Ann E McCullough; Beiyun Chen; Robert B Jenkins; George W Sledge; Eric P Winer; Julie R Gralow; Monica M Reinholz
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.

Authors:  Barbara Ingold Heppner; Michael Untch; Carsten Denkert; Berit M Pfitzner; Bianca Lederer; Wolfgang Schmitt; Holger Eidtmann; Peter A Fasching; Hans Tesch; Christine Solbach; Mahdi Rezai; Dirk M Zahm; Frank Holms; Manfred Glados; Petra Krabisch; Esther Heck; Angelika Ober; Petra Lorenz; Kurt Diebold; Jörg-Olaf Habeck; Sibylle Loibl
Journal:  Clin Cancer Res       Date:  2016-05-17       Impact factor: 12.531

Review 7.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

Authors:  Edward C Stack; Chichung Wang; Kristin A Roman; Clifford C Hoyt
Journal:  Methods       Date:  2014-09-19       Impact factor: 3.608

8.  Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.

Authors:  Elena García-Martínez; Ginés Luengo Gil; Asunción Chaves Benito; Enrique González-Billalabeitia; María Angeles Vicente Conesa; Teresa García García; Elisa García-Garre; Vicente Vicente; Francisco Ayala de la Peña
Journal:  Breast Cancer Res       Date:  2014-11-29       Impact factor: 6.466

9.  Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.

Authors:  M V Dieci; P Conte; G Bisagni; A A Brandes; A Frassoldati; L Cavanna; A Musolino; F Giotta; A Rimanti; O Garrone; E Bertone; K Cagossi; S Sarti; A Ferro; F Piacentini; A Maiorana; E Orvieto; M Sanders; F Miglietta; S Balduzzi; R D'Amico; V Guarneri
Journal:  Ann Oncol       Date:  2019-03-01       Impact factor: 32.976

10.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Authors:  Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544
View more
  14 in total

Review 1.  Clinical trial data and emerging strategies: HER2-positive breast cancer.

Authors:  Sonia Pernas; Sara M Tolaney
Journal:  Breast Cancer Res Treat       Date:  2022-04-09       Impact factor: 4.872

2.  Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.

Authors:  Danielle J Fassler; Luke A Torre-Healy; Rajarsi Gupta; Alina M Hamilton; Soma Kobayashi; Sarah C Van Alsten; Yuwei Zhang; Tahsin Kurc; Richard A Moffitt; Melissa A Troester; Katherine A Hoadley; Joel Saltz
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

3.  Relationship of the standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm.

Authors:  Soeun Park; Eun-Ki Min; Soong June Bae; Chihwan Cha; Dooreh Kim; Janghee Lee; Yoon Jin Cha; Sung Gwe Ahn; Joon Jeong
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

4.  Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.

Authors:  Rashmi Verma; Andrew M Hanby; Kieran Horgan; Eldo T Verghese; Milene Volpato; Clive R Carter; Thomas A Hughes
Journal:  Breast Cancer Res Treat       Date:  2020-06-23       Impact factor: 4.872

5.  Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients.

Authors:  Jiujun Zhu; Dechuang Jiao; Yajie Zhao; Xuhui Guo; Yue Yang; Hui Xiao; Zhenzhen Liu
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

Review 6.  Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.

Authors:  Maria Vittoria Dieci; Federica Miglietta; Valentina Guarneri
Journal:  Cells       Date:  2021-01-23       Impact factor: 6.600

7.  Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.

Authors:  Katherine Sanchez; Isaac Kim; Brie Chun; Joanna Pucilowska; William L Redmond; Walter J Urba; Maritza Martel; Yaping Wu; Mary Campbell; Zhaoyu Sun; Gary Grunkemeier; Shu Ching Chang; Brady Bernard; David B Page
Journal:  Breast Cancer Res       Date:  2021-01-07       Impact factor: 6.466

8.  The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression.

Authors:  Mao Shang; Yajing Chi; Jianbo Zhang; Jin Chang; Hui Yang; Sha Yin; Qiaorui Tan; Xiaochu Man; Huihui Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

9.  Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Fuxing Zhao; Xingfa Huo; Miaozhou Wang; Zhen Liu; Yi Zhao; Dengfeng Ren; Qiqi Xie; Zhilin Liu; Zitao Li; Feng Du; Guoshuang Shen; Jiuda Zhao
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

10.  Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy.

Authors:  Lun Li; Min Chen; Shuyue Zheng; Hanlu Li; Weiru Chi; Bingqiu Xiu; Qi Zhang; Jianjing Hou; Jia Wang; Jiong Wu
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.